SJS Investment Consulting’s Acumen Pharmaceuticals ABOS Stock Holding History

SJS Investment Consulting’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$407	Buy	+183	New	+$473	﹤0.01%	2795

Other funds holding ABOS

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

PWMAG

Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.71B AUM 23.29% 1-Year Est. Return

Clune & Associates Chicago, Illinois $654M AUM 13.19% 1-Year Est. Return

TFC Financial Management Boston, Massachusetts $893M AUM 15.25% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Parkside Financial Bank & Trust Saint Louis, Missouri $1.51B AUM 17.86% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

SJS Investment Consulting's ABOS Position: Q3 2026 in Review

SJS Investment Consulting opened a new position in Acumen Pharmaceuticals (ABOS) in Q3 2026: 183 shares worth $407. The stake represents ﹤0.01% of the portfolio and ranks #2795 among its holdings.

11 funds tracked by Wall St. Rank hold ABOS as of Q3 2026.

SJS Investment Consulting held 183 shares of Acumen Pharmaceuticals worth $407 as of Q3 2026.
Acumen Pharmaceuticals was a new SJS Investment Consulting position in Q3 2026.
Acumen Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #2795 holding.
11 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.